Nkarta, Inc

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies aimed at improving the treatment of immune diseases and cancer. Their lead program, soquelitinib, is a first-in-class oral therapy designed to selectively inhibit ITK, thereby modulating and controlling key signaling pathways within the immune system. Committed to advancing scientific knowledge and patient care, Corvus embraces a culture that fosters leadership, collaboration, and innovation. The company is actively expanding its pipeline while engaging with investors and stakeholders to drive progress in therapeutic development. Generated from the website

Spruce Biosciences, Inc, based in South San Francisco, CA, is dedicated to developing and bringing to market innovative therapies for neurological and endocrine disorders with substantial unmet medical needs. With a focus on patient-centered care, Spruce aims to make a positive impact on the lives of individuals grappling with these challenging conditions. At the core of Spruce's approach is Tildacerfont, a cutting-edge non-steroidal treatment under active investigation for addressing polycystic ovary syndrome (PCOS), major depressive disorder (MDD), and other related disorders. Tildacerfont stands out for its potent and highly selective nature as an oral antagonist of the CRF 1 receptor, crucial for regulating stress response and implicated in various conditions like MDD. Through its pioneering work and commitment to patient well-being, Spruce Biosciences, Inc, stands as a beacon of hope for those navigating complex neurological and endocrine disorders, offering novel therapeutic solutions that have the potential to transform lives. Generated from the website content